Research programme: small molecule therapeutics - Shanghai De Novo Pharmatech

Drug Profile

Research programme: small molecule therapeutics - Shanghai De Novo Pharmatech

Alternative Names: DN 1403; DN 1406; DN 1507; DN 1508; DN 4; QF 036; SC 110237

Latest Information Update: 26 Nov 2016

Price : $50

At a glance

  • Originator Shanghai De Novo Pharmatech
  • Class Small molecules
  • Mechanism of Action Fms-like tyrosine kinase 3 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Acute myeloid leukaemia; Diabetes mellitus; Viral infections

Most Recent Events

  • 24 Nov 2016 Preclinical trials in Acute myeloid leukaemia in China (PO) before November 2016
  • 24 Nov 2016 Preclinical trials in Diabetes mellitus in China (unspecified route) before November 2016
  • 24 Nov 2016 Preclinical trials in Viral infections in China (unspecified route) before November 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top